Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CMPS
CMPS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CMPS News
Compass Pathways to Release New Clinical Data
34m ago
Newsfilter
Trump Administration Blocks FDA Fast-Track for Psychedelic Treatment
Feb 04 2026
seekingalpha
Compass Receives FDA Approval for COMP360 PTSD Clinical Trial
Jan 07 2026
Newsfilter
Compass Pathways Partners with Radial Health to Advance COMP360 Treatment Models
Jan 06 2026
Businesswire
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Dec 10 2025
NASDAQ.COM
COMPASS Pathways Reports ADS GAAP EPS of -$1.44, Falling Short by $1.05
Nov 04 2025
SeekingAlpha
Compass Pathways Names Dr. Jeffrey Jonas to Its Board of Directors
Oct 29 2025
Newsfilter
Compass Pathways Set to Release Q3 Financial Results on November 4, 2025
Oct 28 2025
Newsfilter
Design Therapeutics Names Justin Gover to Board of Directors
Sep 10 2025
Globenewswire
Compass Pathways Reveals Findings from Phase 2 Trial of COMP360 Psilocybin for PTSD
Sep 02 2025
Newsfilter
AbbVie Aims for Psychedelic Depression Treatment Market with $1.2 Billion Agreement
Aug 25 2025
Reuters
Cathie Wood ‘Buys the Dip’ in Block Stock; Sells Shopify Shares
Aug 12 2025
TipRanks
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
Aug 05 2025
Newsfilter
HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $40
Aug 04 2025
Benzinga
Compass (CMPS) Q2 Loss Improves 27%
Aug 01 2025
NASDAQ.COM
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks
Jul 31 2025
SeekingAlpha
Show More News
